The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing ...

Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common ... The study utilized advanced optical genome mapping with single-molecule precision where ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

Other groups advanced FGF1 as well as different FGFs ... phase 2 proof-of-concept trial in patients with Fuchs dystrophy in 2021. The phase 2 trial is enrolling Fuchs dystrophy patients who ...

that is designed to selectively target and reduce the expression of the mutant TCF4 gene that causes corneal endothelial cell dysfunction leading to Fuchs endothelial corneal dystrophy (FECD).